This program provides retina specialists and other ophthalmologists caring for patients with neovascular AMD and DME with a comprehensive overview of sustained-release therapies for retinal diseases. Participants will appraise the latest clinical data on the safety and efficacy of sustained delivery platforms, including the Port Delivery System (PDS) with ranibizumab, and emerging options like tyrosine kinase inhibitors and gene therapies. The program will detail the technical consideration...
All content for MedEdicus Podcasts is the property of MedEdicus and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
This program provides retina specialists and other ophthalmologists caring for patients with neovascular AMD and DME with a comprehensive overview of sustained-release therapies for retinal diseases. Participants will appraise the latest clinical data on the safety and efficacy of sustained delivery platforms, including the Port Delivery System (PDS) with ranibizumab, and emerging options like tyrosine kinase inhibitors and gene therapies. The program will detail the technical consideration...
Thyroid Eye Disease: Conversations on Comprehensive Comanagement: Treatment (CE/CME Podcast) - Part 2
MedEdicus Podcasts
27 minutes
8 months ago
Thyroid Eye Disease: Conversations on Comprehensive Comanagement: Treatment (CE/CME Podcast) - Part 2
This podcast, Part 2 of a 3-part series on thyroid eye disease (TED), provides an in-depth discussion of treatment strategies, focusing on current medical and surgical options as well as emerging therapies. Faculty review clinical data on teprotumumab, the only FDA-approved agent for TED. Listeners will also be introduced to clinical data on treatments including glucocorticoids, orbital radiation, rituximab, and tocilizumab and learn how to select appropriate therapies across a spectrum of di...
MedEdicus Podcasts
This program provides retina specialists and other ophthalmologists caring for patients with neovascular AMD and DME with a comprehensive overview of sustained-release therapies for retinal diseases. Participants will appraise the latest clinical data on the safety and efficacy of sustained delivery platforms, including the Port Delivery System (PDS) with ranibizumab, and emerging options like tyrosine kinase inhibitors and gene therapies. The program will detail the technical consideration...
